Granite Point Capital Management’s PTC Therapeutics PTCT Stock Holding History

Granite Point Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-75,000	Closed	-$818K	–	98
2016 Q4	$818K	Buy	+75,000	New	+$787K	0.65%	50
2016 Q3	–	Sell	-327,579	Closed	-$2.3M	–	109
2016 Q2	$2.3M	Buy	+327,579	New	+$2.4M	0.99%	17
2015 Q4	–	Sell	-35,432	Closed	-$946K	–	95
2015 Q3	$946K	Sell	35,432 -1,036	-3%	-$44.3K	0.65%	39
2015 Q2	$1.75M	Buy	36,468 +16,468	+82%	+$961K	0.51%	27
2015 Q1	$1.22M	Sell	20,000 -53,000	-73%	-$3.23M	0.45%	37
2014 Q4	$3.78M	Buy	73,000 +56,800	+351%	+$2.5M	1.77%	8
2014 Q3	$713K	Buy	+16,200	New	+$507K	0.36%	50
2014 Q1	–	Sell	-50,000	Closed	-$849K	–	111
2013 Q4	$849K	Buy	+50,000	New	+$879K	0.14%	68

Other funds holding PTCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Granite Point Capital Management's PTCT Position: Q1 2017 in Review

Granite Point Capital Management sold out of PTC Therapeutics (PTCT) in Q1 2017, closing a stake of 75,000 shares — an estimated $818K sold.

Granite Point Capital Management first reported a position in PTCT in Q4 2013 and held it in 8 quarters. The position peaked at $3.78M in Q4 2014. 115 funds tracked by Wall St. Rank hold PTCT as of Q1 2017.

Granite Point Capital Management reported no remaining PTC Therapeutics position as of Q1 2017 after selling out during the quarter.
Granite Point Capital Management sold 75,000 PTC Therapeutics shares in Q1 2017, an estimated $818K.
Granite Point Capital Management first reported a position in PTC Therapeutics in Q4 2013 and held it in 8 quarters.
Granite Point Capital Management's PTC Therapeutics position peaked at $3.78M in Q4 2014.
115 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2017.

Based on Granite Point Capital Management's 13F filing for Q1 2017, filed 10 May 2017.